Next Article in Journal / Special Issue
Glioblastoma-Initiating Cells: Relationship with Neural Stem Cells and the Micro-Environment
Previous Article in Journal
The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer
Previous Article in Special Issue
Glioma Surgical Aspirate: A Viable Source of Tumor Tissue for Experimental Research
Article Menu

Export Article

Open AccessReview
Cancers 2013, 5(3), 1020-1048; doi:10.3390/cancers5031020

Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

1
Laboratory of Experimental Neurosurgery and Neuroanatomy, KU Leuven, Leuven 3000, Belgium
2
Laboratory of Pediatric Immunology, KU Leuven, Leuven 3000, Belgium
3
Laboratory of Pharmaceutics and Biopharmaceutics, ULB, Brussels 1050, Belgium
4
Laboratory of Toxicology, ULB, Brussels 1050, Belgium
5
Department of Neurosurgery, Erasmus University Hospitals, Brussels 1050, Belgium
6
Department of Neurosurgery, University Hospitals Leuven, Leuven 3000, Belgium
*
Author to whom correspondence should be addressed.
Received: 29 June 2013 / Revised: 29 June 2013 / Accepted: 2 August 2013 / Published: 14 August 2013
(This article belongs to the Special Issue Glioblastoma)
View Full-Text   |   Download PDF [508 KB, uploaded 14 August 2013]   |  

Abstract

Despite recent advances in tumor imaging and chemoradiotherapy, the median overall survival of patients diagnosed with glioblastoma multiforme does not exceed 15 months. Infiltration of glioma cells into the brain parenchyma, and the blood-brain barrier are important hurdles to further increase the efficacy of classic therapeutic tools. Local administration methods of therapeutic agents, such as convection enhanced delivery and intracerebral injections, are often associated with adverse events. The intranasal pathway has been proposed as a non-invasive alternative route to deliver therapeutics to the brain. This route will bypass the blood-brain barrier and limit systemic side effects. Upon presentation at the nasal cavity, pharmacological agents reach the brain via the olfactory and trigeminal nerves. Recently, formulations have been developed to further enhance this nose-to-brain transport, mainly with the use of nanoparticles. In this review, the focus will be on formulations of pharmacological agents, which increase the nasal permeation of hydrophilic agents to the brain, improve delivery at a constant and slow release rate, protect therapeutics from degradation along the pathway, increase mucoadhesion, and facilitate overall nasal transport. A mounting body of evidence is accumulating that the underexplored intranasal delivery route might represent a major breakthrough to combat glioblastoma.
Keywords: glioblastoma multiforme; intranasal administration; nose-to-brain delivery; formulations; nanoparticles; drug delivery; new therapy concept glioblastoma multiforme; intranasal administration; nose-to-brain delivery; formulations; nanoparticles; drug delivery; new therapy concept
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

van Woensel, M.; Wauthoz, N.; Rosière, R.; Amighi, K.; Mathieu, V.; Lefranc, F.; van Gool, S.W.; de Vleeschouwer, S. Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM? Cancers 2013, 5, 1020-1048.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top